Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 4th edition, 372 pages

+ the daily Top 10

  Lung Cancer

  Free Subscription

Articles published in Int J Cancer

Retrieve available abstracts of 177 articles:
HTML format

Single Articles

    September 2020
  1. DUDNIK E, Moskovitz M, Agbarya A, Gottfried T, et al
    Alternative nivolumab duration and scheduling in advanced non-small cell lung cancer (aNSCLC): a real-world evidence.
    Int J Cancer. 2020 Sep 1. doi: 10.1002/ijc.33281.
    PubMed     Abstract available

    August 2020
  2. YOO JE, Han K, Shin DW, Park SH, et al
    Conditional relative survival and competing mortality in patients who underwent surgery for lung cancer: a nationwide cohort study.
    Int J Cancer. 2020 Aug 1. doi: 10.1002/ijc.33239.
    PubMed     Abstract available

    June 2020
  3. WU D, Nie J, Hu W, Dai L, et al
    A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer.
    Int J Cancer. 2020 Jun 18. doi: 10.1002/ijc.33161.
    PubMed     Abstract available

  4. VELAZQUEZ-KRONEN R, Gilbert ES, Linet MS, Moysich KB, et al
    Lung cancer mortality associated with protracted low-dose occupational radiation exposures and smoking behaviors in U.S. radiologic technologists, 1983-2012.
    Int J Cancer. 2020 Jun 7. doi: 10.1002/ijc.33141.
    PubMed     Abstract available

  5. HOPKINS AM, Wagner J, Kichenadasse G, Modi N, et al
    Patient-reported outcomes as a prognostic marker of survival in patients with advanced non-small cell lung cancer treated with immunotherapy: PROs as a prognostic marker for immunotherapies.
    Int J Cancer. 2020 Jun 3. doi: 10.1002/ijc.33133.
    PubMed     Abstract available

  6. HOU HH, Pan HJ, Liao WY, Lee CH, et al
    Autophagy in fibroblasts induced by cigarette smoke extract promotes invasion in lung cancer cells.
    Int J Cancer. 2020 Jun 3. doi: 10.1002/ijc.33127.
    PubMed     Abstract available

    May 2020
  7. CAI H, Sobue T, Kitamura T, Ishihara J, et al
    Association between Meat and Saturated Fatty Acid Intake and Lung Cancer Risk: The Japan Public Health Center-based Prospective Study.
    Int J Cancer. 2020 May 22. doi: 10.1002/ijc.33112.
    PubMed     Abstract available

  8. TAKAMORI S, Takada K, Shimokawa M, Matsubara T, et al
    Predictive and prognostic impact of primary tumor-bearing lobe in non-small cell lung cancer patients treated with anti-PD-1 therapy.
    Int J Cancer. 2020 May 1. doi: 10.1002/ijc.33030.
    PubMed     Abstract available

  9. DONG S, Ruiz-Calderon B, Rathinam R, Eastlack S, et al
    Knockout model reveals the role of Nischarin in mammary gland development, breast tumorigenesis and response to metformin treatment.
    Int J Cancer. 2020;146:2576-2587.
    PubMed     Abstract available

  10. BERGQVIST M, Christensen HN, Wiklund F, Bergstrom S, et al
    Real world utilization of EGFR TKIs and prognostic factors for survival in NSCLC during 2010-2016 in Sweden: A nationwide observational study.
    Int J Cancer. 2020;146:2510-2517.
    PubMed     Abstract available

    March 2020
  11. HELLMANN MD, Gettinger S, Chow LQM, Gordon M, et al
    Phase 1 Study of Epacadostat in Combination With Atezolizumab for Patients With Previously Treated Advanced Non-Small Cell Lung Cancer.
    Int J Cancer. 2020 Mar 6. doi: 10.1002/ijc.32951.
    PubMed     Abstract available

  12. QI L, Zhang Q, Miao Y, Kang W, et al
    Interleukin-33 activates and recruits natural killer cells to inhibit pulmonary metastatic cancer development.
    Int J Cancer. 2020;146:1421-1434.
    PubMed     Abstract available

    February 2020
  13. TANG D, Zhao YC, Liu H, Luo S, et al
    Potentially functional genetic variants in PLIN2, SULT2A1 and UGT1A9 genes of the Ketone pathway and survival of non-small cell lung cancer.
    Int J Cancer. 2020 Feb 18. doi: 10.1002/ijc.32932.
    PubMed     Abstract available

  14. BRASKY TM, Ray RM, Navarro SL, Schenk JM, et al
    Supplemental one-carbon metabolism related B vitamins and lung cancer risk in the Women's Health Initiative.
    Int J Cancer. 2020 Feb 6. doi: 10.1002/ijc.32913.
    PubMed     Abstract available

  15. FIDLER-BENAOUDIA MM, Torre LA, Bray F, Ferlay J, et al
    Lung cancer incidence in young women vs. young men: A systematic analysis in 40 countries.
    Int J Cancer. 2020 Feb 5. doi: 10.1002/ijc.32809.
    PubMed     Abstract available

    January 2020
  16. HATA A, Nakajima T, Matsusaka K, Fukuyo M, et al
    A low DNA methylation epigenotype in lung squamous cell carcinoma and its association with idiopathic pulmonary fibrosis and poorer prognosis.
    Int J Cancer. 2020;146:388-399.
    PubMed     Abstract available

  17. LOPEZ-PLANA A, Fernandez-Nogueira P, Munoz-Guardiola P, Sole-Sanchez S, et al
    The novel pro-autophagy anticancer drug ABTL0812 potentiates chemotherapy in adenocarcinoma and squamous Non-Small Cell Lung Cancer.
    Int J Cancer. 2020 Jan 14. doi: 10.1002/ijc.32865.
    PubMed     Abstract available

  18. ZHANG L, Wang MJ, Wang W, Zhao JY, et al
    Identification of driver genes and somatic mutations in cell-free DNA of patients with pulmonary lymphangioleiomyomatosis.
    Int J Cancer. 2020;146:103-114.
    PubMed     Abstract available

    December 2019
  19. HSIEH YY, Fang WT, Lo YW, Chen YH, et al
    Comparing the Effectiveness of Different EGFR-TKIs in Patients with EGFR Mutant Non-Small-Cell Lung Cancer: A Retrospective Cohort Study in Taiwan.
    Int J Cancer. 2019 Dec 19. doi: 10.1002/ijc.32841.
    PubMed     Abstract available

  20. MOHRHERR J, Haber M, Breitenecker K, Aigner P, et al
    JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression.
    Int J Cancer. 2019;145:3376-3388.
    PubMed     Abstract available

    November 2019
  21. BOECKX B, Bahadur Shahi R, Smeets D, De Brakeleer S, et al
    The genomic landscape of non-small cell lung carcinoma in never smokers.
    Int J Cancer. 2019 Nov 19. doi: 10.1002/ijc.32797.
    PubMed     Abstract available

  22. JIN R, Li J, Jin Z, Lu Y, et al
    Osimertinib confers potent binding affinity to EGFR kinase domain duplication.
    Int J Cancer. 2019;145:2884-2885.

  23. WATZA D, Lusk CM, Dyson G, Purrington KS, et al
    COPD-dependent effects of genetic variation in key inflammation pathway genes on lung cancer risk.
    Int J Cancer. 2019 Nov 10. doi: 10.1002/ijc.32780.
    PubMed     Abstract available

  24. BOSSE Y, Li Z, Xia J, Manem V, et al
    Transcriptome-wide association study reveals candidate causal genes for lung cancer.
    Int J Cancer. 2019 Nov 6. doi: 10.1002/ijc.32771.
    PubMed     Abstract available

  25. DUAN W, Gao L, Kalvala A, Aguila B, et al
    Type of TP53 mutation influences oncogenic potential and spectrum of associated K-ras mutations in lung-specific transgenic mice.
    Int J Cancer. 2019;145:2418-2426.
    PubMed     Abstract available

    October 2019
  26. YANG S, Tang D, Zhao YC, Liu H, et al
    Novel genetic variants in KIF16B and NEDD4L in the endosome-related genes are associated with non-small cell lung cancer survival.
    Int J Cancer. 2019 Oct 16. doi: 10.1002/ijc.32739.
    PubMed     Abstract available

  27. QIAN J, Nie W, Lu J, Zhang L, et al
    Racial differences in characteristics and prognoses between Asian and white patients with non-small cell lung cancer receiving atezolizumab: an ancillary analysis of the POPLAR and OAK studies.
    Int J Cancer. 2019 Oct 3. doi: 10.1002/ijc.32717.
    PubMed     Abstract available

  28. STAPELFELD C, Dammann C, Maser E
    Sex-specificity in lung cancer risk.
    Int J Cancer. 2019 Oct 3. doi: 10.1002/ijc.32716.
    PubMed     Abstract available

  29. DAI J, Huang M, Amos CI, Hung RJ, et al
    Genome-wide association study of INDELs identified four novel susceptibility loci associated with lung cancer risk.
    Int J Cancer. 2019 Oct 2. doi: 10.1002/ijc.32698.
    PubMed     Abstract available

  30. KUANG M, Zheng D, Tao X, Peng Y, et al
    tRNA-based prognostic score in predicting survival outcomes of lung adenocarcinomas.
    Int J Cancer. 2019;145:1982-1990.
    PubMed     Abstract available

    September 2019
  31. WU DM, Deng SH, Zhou J, Han R, et al
    PLEK2 mediates metastasis and vascular invasion via the ubiquitin-dependent degradation of SHIP2 in non-small cell lung cancer.
    Int J Cancer. 2019 Sep 9. doi: 10.1002/ijc.32675.
    PubMed     Abstract available

  32. JIA Y, Li X, Jiang T, Zhao S, et al
    EGFR-targeted therapy alters the tumor microenvironment in EGFR-driven lung tumors: Implications for combination therapies.
    Int J Cancer. 2019;145:1432-1444.
    PubMed     Abstract available

  33. GRUNEWALD S, Politz O, Bender S, Heroult M, et al
    Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.
    Int J Cancer. 2019;145:1346-1357.
    PubMed     Abstract available

    August 2019
  34. KANG J, Chang Y, Ahn J, Oh S, et al
    Neutrophil-to-lymphocyte ratio and risk of lung cancer mortality in a low-risk population: A cohort study.
    Int J Cancer. 2019 Aug 27. doi: 10.1002/ijc.32640.
    PubMed     Abstract available

  35. NEMETH E, Krzystanek M, Reiniger L, Ribli D, et al
    The genomic imprint of cancer therapies helps timing the formation of metastases.
    Int J Cancer. 2019;145:694-704.
    PubMed     Abstract available

  36. VOLCKMAR AL, Leichsenring J, Kirchner M, Christopoulos P, et al
    Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases.
    Int J Cancer. 2019;145:649-661.
    PubMed     Abstract available

    July 2019
  37. GURTNER K, Kryzmien Z, Koi L, Wang M, et al
    Radioresistance of KRAS/TP53-Mutated Lung Cancer can be overcome by Radiation Dose Escalation or EGFR Tyrosine Kinase Inhibition In Vivo.
    Int J Cancer. 2019 Jul 29. doi: 10.1002/ijc.32598.
    PubMed     Abstract available

  38. BAI L, Shin S, Burnett RT, Kwong JC, et al
    Exposure to ambient air pollution and the incidence of lung cancer and breast cancer in the Ontario Population Health and Environment Cohort (ONPHEC).
    Int J Cancer. 2019 Jul 15. doi: 10.1002/ijc.32575.
    PubMed     Abstract available

  39. KINOSHITA R, Sato H, Yamauchi A, Takahashi Y, et al
    Newly developed anti-S100A8/A9 monoclonal antibody efficiently prevents lung tropic cancer metastasis.
    Int J Cancer. 2019;145:569-575.
    PubMed     Abstract available

  40. HUANG JY, Larose TL, Luu HN, Wang R, et al
    Circulating markers of cellular immune activation in pre-diagnostic blood sample and lung cancer risk in the Lung Cancer Cohort Consortium (LC3).
    Int J Cancer. 2019 Jul 5. doi: 10.1002/ijc.32555.
    PubMed     Abstract available

  41. YI L, Fan J, Qian R, Luo P, et al
    Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis.
    Int J Cancer. 2019;145:284-294.
    PubMed     Abstract available

  42. BI L, Xie C, Yao M, Thae Hnit SS, et al
    The histone chaperone complex FACT promotes proliferative switch of G0 cancer cells.
    Int J Cancer. 2019;145:164-178.
    PubMed     Abstract available

    June 2019
  43. ZHANG L, Yang Y, Chai L, Bu H, et al
    FRK plays an oncogenic role in nonsmall cell lung cancer by enhancing the stemness phenotype via induction of metabolic reprogramming.
    Int J Cancer. 2019 Jun 28. doi: 10.1002/ijc.32530.
    PubMed     Abstract available

  44. KINOSHITA R, Sato H, Yamauchi A, Takahashi Y, et al
    exSSSRs (extracellular S100 soil sensor receptors)-Fc fusion proteins work as prominent decoys to S100A8/A9-induced lung tropic cancer metastasis.
    Int J Cancer. 2019;144:3138-3145.
    PubMed     Abstract available

  45. TAKASHIMA Y, Kikuchi E, Kikuchi J, Suzuki M, et al
    Bromodomain and Extraterminal Domain Inhibition Synergizes with WEE1-Inhibitor AZD1775 Effect by Impairing Non-Homologous End Joining and Enhancing DNA Damage in Non-Small Cell Lung Cancer.
    Int J Cancer. 2019 Jun 14. doi: 10.1002/ijc.32515.
    PubMed     Abstract available

  46. BECKER N, Motsch E, Trotter A, Heussel CP, et al
    Lung cancer mortality reduction by LDCT screening - results from the randomised German LUSI trial.
    Int J Cancer. 2019 Jun 4. doi: 10.1002/ijc.32486.
    PubMed     Abstract available

  47. LIU YN, Tsai MF, Wu SG, Chang TH, et al
    Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer.
    Int J Cancer. 2019 Jun 4. doi: 10.1002/ijc.32487.
    PubMed     Abstract available

    May 2019
  48. GAO X, Wilsgaard T, Jansen EH, Xuan Y, et al
    Serum total thiol levels and the risk of lung, colorectal, breast and prostate cancer: A prospective case-cohort study.
    Int J Cancer. 2019 May 24. doi: 10.1002/ijc.32428.
    PubMed     Abstract available

  49. JIANG T, Chu Q, Wang H, Zhou F, et al
    EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases.
    Int J Cancer. 2019;144:2605-2612.
    PubMed     Abstract available

  50. ENDRIS V, Buchhalter I, Allgauer M, Rempel E, et al
    Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels.
    Int J Cancer. 2019;144:2303-2312.
    PubMed     Abstract available

    April 2019
  51. QU J, Liu L, Xu Q, Ren J, et al
    CARD9 protects lung cancer development by suppressing the expansion of myeloid-derived suppressor cells and IDO production.
    Int J Cancer. 2019 Apr 22. doi: 10.1002/ijc.32355.
    PubMed     Abstract available

  52. D'ANDREA E, Choudhry NK, Raby B, Weinhouse GL, et al
    A bronchial-airway gene-expression classifier to improve the diagnosis of lung cancer: clinical outcomes and cost-effectiveness analysis.
    Int J Cancer. 2019 Apr 11. doi: 10.1002/ijc.32333.
    PubMed     Abstract available

  53. WANG S, Zhang J, He Z, Wu K, et al
    The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients' sex.
    Int J Cancer. 2019 Apr 10. doi: 10.1002/ijc.32327.
    PubMed     Abstract available

  54. ZHANG B, Wu Q
    Erratum: The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer.
    Int J Cancer. 2019;144:E2.

  55. WANG L, Zhao H, Xu Y, Li J, et al
    Systematic identification of lincRNA-based prognostic biomarkers by integrating lincRNA expression and copy number variation in lung adenocarcinoma.
    Int J Cancer. 2019;144:1723-1734.
    PubMed     Abstract available

    March 2019
  56. DIETZ S, Lifshitz A, Kazdal D, Harms A, et al
    Global DNA methylation reflects spatial heterogeneity and molecular evolution of lung adenocarcinomas.
    Int J Cancer. 2019;144:1061-1072.
    PubMed     Abstract available

    February 2019
  57. SHIN SH, Park HY, Im Y, Jung HA, et al
    Improved Treatment Outcome of Pembrolizumab in Patients with Non-small Cell Lung Cancer and Chronic Obstructive Pulmonary Disease.
    Int J Cancer. 2019 Feb 26. doi: 10.1002/ijc.32235.
    PubMed     Abstract available

  58. LEUNG EL, Luo LX, Li Y, Liu ZQ, et al
    Identification of a new inhibitor of KRAS-PDEdelta interaction targeting KRAS mutant non-small cell lung cancer.
    Int J Cancer. 2019 Feb 20. doi: 10.1002/ijc.32222.
    PubMed     Abstract available

  59. ZHANG C, Ding H, Huang H, Palashati H, et al
    TCR repertoire intratumor heterogeneity of CD4(+) and CD8(+) T cells in centers and margins of localized lung adenocarcinomas.
    Int J Cancer. 2019;144:818-827.
    PubMed     Abstract available

  60. SONG H, Sun B, Liao Y, Xu D, et al
    GPRC5A deficiency leads to dysregulated MDM2 via activated EGFR signaling for lung tumor development.
    Int J Cancer. 2019;144:777-787.
    PubMed     Abstract available

    January 2019
  61. YANG L, Dong Y, Li Y, Wang D, et al
    IL-10 derived from M2 macrophage promotes cancer stemness via JAK1/STAT1/NF-kappaB/Notch1 pathway in non-small cell lung cancer.
    Int J Cancer. 2019 Jan 22. doi: 10.1002/ijc.32151.
    PubMed     Abstract available

  62. LIU Y, Yang Q, Yang J, Cao R, et al
    Characteristics and prognostic significance of profiling the peripheral blood T-cell receptor repertoire in patients with advanced lung cancer.
    Int J Cancer. 2019 Jan 21. doi: 10.1002/ijc.32145.
    PubMed     Abstract available

  63. CHEN K, Liu H, Liu Z, Luo S, et al
    Genetic Variants in RUNX3, AMD1 and MSRA in the Methionine Metabolic Pathway and Survival in Non-small Cell Lung Cancer Patients.
    Int J Cancer. 2019 Jan 16. doi: 10.1002/ijc.32128.
    PubMed     Abstract available

  64. PAN Y, Yuan C, Cheng C, Zhang Y, et al
    Frequency and clinical significance of NF1 mutation in lung adenocarcinomas from East Asian patients.
    Int J Cancer. 2019;144:290-296.
    PubMed     Abstract available

  65. DU Y, Song W, Chen J, Chen H, et al
    The potassium channel KCa3.1 promotes cell proliferation by activating SKP2 and metastasis through the EMT pathway in hepatocellular carcinoma.
    Int J Cancer. 2019 Jan 10. doi: 10.1002/ijc.32121.
    PubMed     Abstract available

  66. DEVAUD C, Tilkin-Mariame AF, Vignolle-Vidoni A, Souleres P, et al
    FAK alternative splice mRNA variants expression pattern in colorectal cancer.
    Int J Cancer. 2019 Jan 10. doi: 10.1002/ijc.32120.
    PubMed     Abstract available

  67. WANG R, Peng S, Zhang X, Wu Z, et al
    Inhibition of NF-kappaB improves sensitivity to irradiation and EGFR-TKIs and decreases irradiation-induced lung toxicity.
    Int J Cancer. 2019;144:200-209.
    PubMed     Abstract available

  68. CHRISTOPOULOS P, Kirchner M, Bozorgmehr F, Endris V, et al
    Identification of a highly lethal V3(+) TP53(+) subset in ALK(+) lung adenocarcinoma.
    Int J Cancer. 2019;144:190-199.
    PubMed     Abstract available

    December 2018
  69. GAO X, Wilsgaard T, Jansen EH, Holleczek B, et al
    Pre-diagnostic derivatives of reactive oxygen metabolites and the occurrence of lung, colorectal, breast and prostate cancer: An individual participant data meta-analysis of two large population-based studies.
    Int J Cancer. 2018 Dec 18. doi: 10.1002/ijc.32073.
    PubMed     Abstract available

  70. LUO J, Chimge NO, Zhou B, Flodby P, et al
    CLDN18.1 attenuates malignancy and related signaling pathways of lung adenocarcinoma in vivo and in vitro.
    Int J Cancer. 2018;143:3169-3180.
    PubMed     Abstract available

  71. MARWITZ S, Heinbockel L, Scheufele S, Kugler C, et al
    Fountain of youth for squamous cell carcinomas? On the epigenetic age of non-small cell lung cancer and corresponding tumor-free lung tissues.
    Int J Cancer. 2018;143:3061-3070.
    PubMed     Abstract available

  72. LYU Z, Li N, Wang G, Feng X, et al
    Independent and joint associations of blood lipids and lipoproteins with lung cancer risk in Chinese males: A prospective cohort study.
    Int J Cancer. 2018 Dec 11. doi: 10.1002/ijc.32051.
    PubMed     Abstract available

  73. DE WIT S, Rossi E, Weber S, Tamminga M, et al
    Single tube liquid biopsy for advanced non-small cell lung cancer.
    Int J Cancer. 2018 Dec 11. doi: 10.1002/ijc.32056.

  74. WONG JYY, Downward GS, Hu W, Portengen L, et al
    Lung Cancer Risk by Geologic Coal Deposits: A Case-Control Study of Female Never-smokers from Xuanwei and Fuyuan, China.
    Int J Cancer. 2018 Dec 3. doi: 10.1002/ijc.32034.
    PubMed     Abstract available

  75. GE Q, Lu M, Ju L, Qian K, et al
    miR-4324-RACGAP1-STAT3-ESR1 feedback loop inhibits proliferation and metastasis of bladder cancer.
    Int J Cancer. 2018 Dec 3. doi: 10.1002/ijc.32036.
    PubMed     Abstract available

  76. WU Y, Lin L, Shen Y, Wu H, et al
    Comparison between PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, and atezolizumab) in pretreated NSCLC patients: Evidence from a Bayesian network model.
    Int J Cancer. 2018;143:3038-3040.

    November 2018
  77. FANIDI A, Carreras-Torres R, Larose TL, Yuan JM, et al
    Is high vitamin B12 status a cause of lung cancer?
    Int J Cancer. 2018 Nov 29. doi: 10.1002/ijc.32033.
    PubMed     Abstract available

  78. LIN YT, Chen JS, Liao WY, Ho CC, et al
    Clinical Outcomes and Secondary Epidermal Growth Factor Receptor (EGFR) T790M Mutation among First-line Gefitinib, Erlotinib and Afatinib-treated Non-small Cell Lung Cancer Patients with Activating EGFR Mutations.
    Int J Cancer. 2018 Nov 28. doi: 10.1002/ijc.32025.
    PubMed     Abstract available

  79. WANG S, Yan B, Zhang Y, Xu J, et al
    Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation.
    Int J Cancer. 2018 Nov 25. doi: 10.1002/ijc.32015.
    PubMed     Abstract available

  80. ZHENG S, Luo X, Dong C, Zheng D, et al
    A B7-CD28 family based signature demonstrates significantly different prognoses and tumor immune landscapes in lung adenocarcinoma.
    Int J Cancer. 2018;143:2592-2601.
    PubMed     Abstract available

  81. NARDI I, Reno T, Yun X, Sztain T, et al
    Triptolide inhibits Wnt signaling in NSCLC through upregulation of multiple Wnt inhibitory factors via epigenetic modifications to Histone H3.
    Int J Cancer. 2018;143:2470-2478.
    PubMed     Abstract available

  82. ZHAO S, Zhang Z, Zhang Y, Hong S, et al
    Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer.
    Int J Cancer. 2018 Nov 14. doi: 10.1002/ijc.31995.
    PubMed     Abstract available

  83. FORTUNATO O, Borzi C, Milione M, Centonze G, et al
    Circulating mir-320a promotes immunosuppressive macrophages M2 phenotype associated with lung cancer risk.
    Int J Cancer. 2018 Nov 13. doi: 10.1002/ijc.31988.
    PubMed     Abstract available

  84. POTJER TP, Bollen S, Grimbergen AJEM, van Doorn R, et al
    Multi-gene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families.
    Int J Cancer. 2018 Nov 10. doi: 10.1002/ijc.31984.
    PubMed     Abstract available

  85. CAI MC, Chen M, Ma P, Wu J, et al
    Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer.
    Int J Cancer. 2018 Nov 8. doi: 10.1002/ijc.31975.
    PubMed     Abstract available

    October 2018
  86. XIA Y, Cai XY, Fan JQ, Zhang LL, et al
    The role of sema4D in vasculogenic mimicry formation in non-small cell lung cancer and the underlying mechanisms.
    Int J Cancer. 2018 Oct 29. doi: 10.1002/ijc.31958.
    PubMed     Abstract available

  87. LI W, Sparidans RW, Wang Y, Lebre MC, et al
    P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
    Int J Cancer. 2018;143:2029-2038.
    PubMed     Abstract available

  88. YANG YG, Koh YW, Sari IN, Jun N, et al
    Interferon-induced transmembrane protein 1-mediated EGFR/SOX2 signaling axis is essential for progression of non-small cell lung cancer.
    Int J Cancer. 2018 Oct 14. doi: 10.1002/ijc.31926.
    PubMed     Abstract available

  89. MATSUO N, Azuma K, Hattori S, Ohtake J, et al
    Association between soluble immune mediators and tumor responses in patients with non-small cell lung cancer treated with anti-PD-1 inhibitor.
    Int J Cancer. 2018 Oct 11. doi: 10.1002/ijc.31923.
    PubMed     Abstract available

    September 2018
  90. QIAN D, Liu H, Wang X, Ge J, et al
    Potentially functional genetic variants in the complement-related immunity gene-set are associated with non-small cell lung cancer survival.
    Int J Cancer. 2018 Sep 27. doi: 10.1002/ijc.31896.
    PubMed     Abstract available

  91. TREUE D, Bockmayr M, Stenzinger A, Heim D, et al
    Proteogenomic systems analysis identifies targeted therapy resistance mechanisms in EGFR-mutated lung cancer.
    Int J Cancer. 2018 Sep 5. doi: 10.1002/ijc.31845.
    PubMed     Abstract available

  92. MAEDA T, Hayashi T, Furukawa H, Iwasaki D, et al
    Immune-mediated antitumor effect of a transplanted lymph node.
    Int J Cancer. 2018;143:1224-1235.
    PubMed     Abstract available

  93. GARCIA-MONCLUS S, Lopez-Alemany R, Almacellas-Rabaiget O, Herrero-Martin D, et al
    EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma.
    Int J Cancer. 2018;143:1188-1201.
    PubMed     Abstract available

  94. XU H, Zhu X, Bao H, Wh Shek T, et al
    Genetic and clonal dissection of osteosarcoma progression and lung metastasis.
    Int J Cancer. 2018;143:1134-1142.
    PubMed     Abstract available

    August 2018
  95. LEHMAN JM, Hoeksema MD, Staub J, Qian J, et al
    Somatostatin Receptor 2 signaling promotes growth and tumor survival in Small Cell Lung Cancer.
    Int J Cancer. 2018 Aug 28. doi: 10.1002/ijc.31771.
    PubMed     Abstract available

  96. JIANG Y, Dai H, Li Y, Yin J, et al
    PARP Inhibitors Synergize with Gemcitabine by Potentiating DNA Damage in Non-Small Cell Lung Cancer.
    Int J Cancer. 2018 Aug 28. doi: 10.1002/ijc.31770.
    PubMed     Abstract available

    July 2018
  97. YUAN Q, Chen X, Han Y, Lei T, et al
    Modification of alpha2,6-sialylation mediates the invasiveness and tumorigenicity of non-small cell lung cancer cells in vitro and in vivo via Notch1/Hes1/MMPs pathway.
    Int J Cancer. 2018 Jul 7. doi: 10.1002/ijc.31737.
    PubMed     Abstract available

  98. XU Y, Liu H, Liu S, Wang Y, et al
    Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31660.
    PubMed     Abstract available

  99. YANG CC, Chang CK, Chang MT, Shyur LF, et al
    Plant galactolipid dLGG suppresses lung metastasis of melanoma through deregulating TNF-alpha-mediated pulmonary vascular permeability and circulating oxylipin dynamics in mice.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31663.
    PubMed     Abstract available

  100. WU Y, Ju Q, Jia K, Yu J, et al
    Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors).
    Int J Cancer. 2018;143:45-51.
    PubMed     Abstract available

  101. TAN J, Fu L, Chen H, Guan J, et al
    Association study of genetic variation in the autophagy lysosome pathway genes and risk of eight kinds of cancers.
    Int J Cancer. 2018;143:80-87.
    PubMed     Abstract available

    June 2018
  102. LEE YM, Kim SJ, Lee JH, Ha E, et al
    Inhaled corticosteroids in COPD and the risk of lung cancer.
    Int J Cancer. 2018 Jun 26. doi: 10.1002/ijc.31632.
    PubMed     Abstract available

  103. BOYSEN AK, Spindler KL, Hoyer M, Mortensen FV, et al
    Metastasis directed therapy for liver and lung metastases from colorectal cancer - a population based study.
    Int J Cancer. 2018 Jun 19. doi: 10.1002/ijc.31626.
    PubMed     Abstract available

  104. LUU HN, Cai H, Murff HJ, Xiang YB, et al
    A Prospective Study of Dietary Polyunsaturated Fatty Acids Intake and Lung Cancer Risk.
    Int J Cancer. 2018 Jun 15. doi: 10.1002/ijc.31608.
    PubMed     Abstract available

  105. LINDNER LH, Litiere S, Sleijfer S, Benson C, et al
    Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarc
    Int J Cancer. 2018;142:2610-2620.
    PubMed     Abstract available

  106. CHRISTOPOULOS P, Endris V, Bozorgmehr F, Elsayed M, et al
    EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK(+) non-small cell lung cancer.
    Int J Cancer. 2018;142:2589-2598.
    PubMed     Abstract available

  107. WANG H, Zhang X, Vidaurre I, Cai R, et al
    Inhibition of experimental small-cell and non-small-cell lung cancers by novel antagonists of growth hormone-releasing hormone.
    Int J Cancer. 2018;142:2394-2404.
    PubMed     Abstract available

  108. YUAN JM, Beckman KB, Wang R, Bull C, et al
    Leukocyte telomere length in relation to risk of lung adenocarcinoma incidence: Findings from the Singapore Chinese Health Study.
    Int J Cancer. 2018;142:2234-2243.
    PubMed     Abstract available

    May 2018
  109. VON NEUBECK B, Gondi G, Riganti C, Pan C, et al
    An inhibitory antibody targeting Carbonic Anhydrase XII abrogates chemoresistance and significantly reduces lung metastases in an orthotopic breast cancer model in vivo.
    Int J Cancer. 2018 May 22. doi: 10.1002/ijc.31607.
    PubMed     Abstract available

  110. LA MANNA S, Lee E, Ouzounova M, Di Natale C, et al
    Mimetics of Suppressor of cytokine signalling 3: novel potential therapeutics in triple breast cancer.
    Int J Cancer. 2018 May 11. doi: 10.1002/ijc.31594.
    PubMed     Abstract available

  111. OH E, Kim YJ, An H, Sung D, et al
    Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition.
    Int J Cancer. 2018 May 9. doi: 10.1002/ijc.31585.
    PubMed     Abstract available

  112. TZENG HT, Su CC, Chang CP, Lai WW, et al
    Rab37 in lung cancer mediates exocytosis of soluble ST2 and thus skews macrophages towards tumor-suppressing phenotype.
    Int J Cancer. 2018 May 1. doi: 10.1002/ijc.31569.
    PubMed     Abstract available

  113. XIE J, Shen K, Lenchine RV, Gethings LA, et al
    Eukaryotic elongation factor 2 kinase upregulates the expression of proteins implicated in cell migration and cancer cell metastasis.
    Int J Cancer. 2018;142:1865-1877.
    PubMed     Abstract available

    April 2018
  114. LA FLEUR L, Boura VF, Alexeyenko A, Berglund A, et al
    Expression of scavenger receptor MARCO defines a targetable tumor-associated macrophage subset in non-small cell lung cancer.
    Int J Cancer. 2018 Apr 18. doi: 10.1002/ijc.31545.
    PubMed     Abstract available

    March 2018
  115. HYNDS RE, Ben Aissa A, Gowers KHC, Watkins TBK, et al
    Expansion of airway basal epithelial cells from primary human non-small cell lung cancer tumors.
    Int J Cancer. 2018 Mar 22. doi: 10.1002/ijc.31383.
    PubMed     Abstract available

  116. BOYAR CETINKAYA R, Aagnes B, Myklebust TA, Thiis-Evensen E, et al
    Survival in neuroendocrine neoplasms; A report from a large Norwegian population-based study.
    Int J Cancer. 2018;142:1139-1147.
    PubMed     Abstract available

  117. PASSIGLIA F, Galvano A, Rizzo S, Incorvaia L, et al
    Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab.
    Int J Cancer. 2018;142:1277-1284.
    PubMed     Abstract available

  118. GAO Y, Yang J, Cai Y, Fu S, et al
    IFN-gamma-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling.
    Int J Cancer. 2018 Mar 8. doi: 10.1002/ijc.31357.
    PubMed     Abstract available

  119. WANG Y, Wang C, Zhang J, Zhu M, et al
    Interaction analysis between germline susceptibility loci and somatic alterations in lung cancer.
    Int J Cancer. 2018 Mar 1. doi: 10.1002/ijc.31351.
    PubMed     Abstract available

    February 2018
  120. WEI Y, Zhou F, Zhou H, Huang J, et al
    Endothelial progenitor cells contribute to neovascularization of non-small cell lung cancer via HDAC7 mediated cytoskeleton regulation and angiogenic genes transcription.
    Int J Cancer. 2018 Feb 28. doi: 10.1002/ijc.31349.
    PubMed     Abstract available

  121. CHO J, Kim S, Du J, Meyerson M, et al
    Autophosphorylation of the C-terminal domain is not required for oncogenic transformation by lung-cancer derived EGFR mutants.
    Int J Cancer. 2018 Feb 21. doi: 10.1002/ijc.31332.
    PubMed     Abstract available

  122. LI X, Wang Y, Wang J, Zhang T, et al
    Enhanced efficacy of AZD3759 and radiation on brain metastasis from EGFR mutant non-small cell lung cancer.
    Int J Cancer. 2018 Feb 12. doi: 10.1002/ijc.31303.
    PubMed     Abstract available

  123. JIANG Z, Chen T, Chen J, Ying S, et al
    Hand-spinning chrysotile exposure and risk of malignant mesothelioma: A case-control study in Southeastern China.
    Int J Cancer. 2018;142:514-523.
    PubMed     Abstract available

    January 2018
  124. NARITA S, Saito E, Sawada N, Shimazu T, et al
    Dietary Consumption of Antioxidant Vitamins and Subsequent Lung Cancer Risk: The Japan Public Health Center-based Prospective Study.
    Int J Cancer. 2018 Jan 22. doi: 10.1002/ijc.31268.
    PubMed     Abstract available

  125. SETTE G, Salvati V, Giordani I, Pillozzi E, et al
    Conditionally reprogrammed cells (CRC) methodology does not allow the in vitro expansion of patient-derived primary and metastatic lung cancer cells.
    Int J Cancer. 2018 Jan 17. doi: 10.1002/ijc.31260.
    PubMed     Abstract available

  126. INOUE-CHOI M, Hartge P, Liao LM, Caporaso N, et al
    Association between long-term low-intensity cigarette smoking and incidence of smoking-related cancer in the national institutes of health-AARP cohort.
    Int J Cancer. 2018;142:271-280.
    PubMed     Abstract available

  127. XU X, Huang Z, Zheng L, Fan Y, et al
    The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer.
    Int J Cancer. 2018 Jan 10. doi: 10.1002/ijc.31252.
    PubMed     Abstract available

  128. MORRIS S, Vachani A, Pass HI, Rom WN, et al
    Whole Blood FPR1 mRNA Expression Predicts Both Non-Small Cell and Small Cell Lung Cancer.
    Int J Cancer. 2018 Jan 5. doi: 10.1002/ijc.31245.
    PubMed     Abstract available

  129. YANG TY, Teng CJ, Lin TC, Chen KC, et al
    Transcriptional repression of Aurora-A gene by wild-type p53 through directly binding to its promoter with histone deacetylase 1 and mSin3a.
    Int J Cancer. 2018;142:92-108.
    PubMed     Abstract available

    December 2017
  130. DAI L, Smith CD, Foroozesh M, Miele L, et al
    The sphingosine kinase 2 inhibitor ABC294640 displays anti-non-small cell lung cancer activities in vitro and in vivo.
    Int J Cancer. 2017 Dec 26. doi: 10.1002/ijc.31234.
    PubMed     Abstract available

  131. YU Y, Jin H, Xu J, Gu J, et al
    XIAP overexpression promotes bladder cancer invasion in vitro and lung metastasis in vivo via enhancing nucleolin-mediated Rho-GDIbeta mRNA stability.
    Int J Cancer. 2017 Dec 18. doi: 10.1002/ijc.31223.
    PubMed     Abstract available

  132. WU Y, Shi H, Jiang M, Qiu M, et al
    The clinical value of combination of immune checkpoint inhibitors in cancer patients: A meta-analysis of efficacy and safety.
    Int J Cancer. 2017;141:2562-2570.
    PubMed     Abstract available

  133. THEOFYLAKTOPOULOU D, Midttun O, Ueland PM, Meyer K, et al
    Impaired functional vitamin B6 status is associated with increased risk of lung cancer.
    Int J Cancer. 2017 Dec 14. doi: 10.1002/ijc.31215.
    PubMed     Abstract available

  134. ZHENG Y, Deng Z, Yin J, Wang S, et al
    The association of genetic variations in DNA repair pathways with severe toxicities in NSCLC patients undergoing platinum-based chemotherapy.
    Int J Cancer. 2017;141:2336-2347.
    PubMed     Abstract available

    Letter to the Editor: Re: The Impact of Overdiagnosis on the Selection of Efficient Lung Cancer Screening Strategies.
    Int J Cancer. 2017 Dec 1. doi: 10.1002/ijc.31185.

    November 2017
  136. WANG Y, Wu W, Zhu M, Wang C, et al
    Integrating expression related SNPs into genome-wide gene-pathway-based analysis identified novel lung cancer susceptibility genes.
    Int J Cancer. 2017 Nov 30. doi: 10.1002/ijc.31182.
    PubMed     Abstract available

  137. ZHAO S, Gao F, Zhang Y, Zhang Z, et al
    Bevacizumab in Combination with Different Platinum-based Doublets in the First-line Treatment for Advanced Nonsquamous Non-small-cell Lung Cancer: A Network Meta-Analysis.
    Int J Cancer. 2017 Nov 24. doi: 10.1002/ijc.31175.
    PubMed     Abstract available

  138. LI Y, Ye Z, Chen S, Pan Z, et al
    ARHGEF19 interacts with BRAF to activate MAPK signaling during the tumorigenesis of non-small cell lung cancer.
    Int J Cancer. 2017 Nov 22. doi: 10.1002/ijc.31169.
    PubMed     Abstract available

  139. SATTERFIELD L, Shuck R, Kurenbekova L, Allen-Rhoades W, et al
    miR-130b directly targets ARHGAP1 to drive activation of a metastatic CDC42-PAK1-AP1 positive feedback loop in Ewing sarcoma.
    Int J Cancer. 2017;141:2062-2075.
    PubMed     Abstract available

  140. KIM J, Field A, Schultz KAP, Hill DA, et al
    The prevalence of DICER1 pathogenic variation in population databases.
    Int J Cancer. 2017;141:2030-2036.
    PubMed     Abstract available

  141. UNVER N, Delgado O, Zeleke K, Cumpian A, et al
    Reduced IL-6 levels and tumor-associated phospho-STAT3 are associated with reduced tumor development in a mouse model of lung cancer chemoprevention with myo-inositol.
    Int J Cancer. 2017 Nov 14. doi: 10.1002/ijc.31152.
    PubMed     Abstract available

  142. ZHANG R, Jia M, Xu Y, Qian D, et al
    ERCC4 regulatory variant predict Grade-3 or -4 toxicities in patients with advanced non-small cell lung cancer treated by platinum-based therapy.
    Int J Cancer. 2017 Nov 14. doi: 10.1002/ijc.31153.
    PubMed     Abstract available

  143. DIETZ S, Harms A, Endris V, Eichhorn F, et al
    Spatial distribution of EGFR and KRAS mutation frequencies correlates with histological growth patterns of lung adenocarcinomas.
    Int J Cancer. 2017;141:1841-1848.
    PubMed     Abstract available

    October 2017
  144. FUJIMOTO J, Nunomura-Nakamura S, Liu Y, Lang W, et al
    Development of Kras mutant lung adenocarcinoma in mice with knockout of the airway lineage-specific gene Gprc5a.
    Int J Cancer. 2017;141:1589-1599.
    PubMed     Abstract available

  145. LIU HX, Tao LL, Zhang J, Zhu YG, et al
    Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects.
    Int J Cancer. 2017 Oct 11. doi: 10.1002/ijc.31098.
    PubMed     Abstract available

    September 2017
  146. BRYANT JL, Gieling RG, Meredith SL, Allen TJ, et al
    Novel carbonic anhydrase IX-targeted therapy enhances the anti-tumour effects of cisplatin in small cell lung cancer.
    Int J Cancer. 2017 Sep 14. doi: 10.1002/ijc.31042.
    PubMed     Abstract available

    August 2017
  147. ZHANG K, Wang J, Tong TR, Wu X, et al
    Loss of H2B monoubiquitination is associated with poor-differentiation and enhanced malignancy of lung adenocarcinoma.
    Int J Cancer. 2017;141:766-777.
    PubMed     Abstract available

  148. GUPTA SK, Guzman EAT, Meenach SA
    Co-administration of a tumor-penetrating peptide improves the therapeutic efficacy of paclitaxel in a novel air-grown lung cancer 3D spheroid model.
    Int J Cancer. 2017 Aug 2. doi: 10.1002/ijc.30913.
    PubMed     Abstract available

    July 2017
  149. LI W, Xie SH, Tse LA, Lagergren J, et al
    Digitalis Use and Lung Cancer Risk by Histological Type in Men.
    Int J Cancer. 2017 Jul 27. doi: 10.1002/ijc.30908.
    PubMed     Abstract available

  150. MORAVCIKOVA E, Krepela E, Donnenberg VS, Donnenberg AD, et al
    BOK displays cell death-independent tumor suppressor activity in non-small cell lung carcinoma.
    Int J Cancer. 2017 Jul 26. doi: 10.1002/ijc.30906.
    PubMed     Abstract available

  151. KETTUNEN E, Hernandez-Vargas H, Cros MP, Durand G, et al
    Asbestos-associated genome-wide DNA methylation changes in lung cancer.
    Int J Cancer. 2017 Jul 19. doi: 10.1002/ijc.30897.
    PubMed     Abstract available

  152. LEE WY, Chen PC, Wu WS, Wu HC, et al
    Panobinostat Sensitizes KRAS-Mutant Non-Small Cell Lung Cancer to Gefitinib by Targeting TAZ.
    Int J Cancer. 2017 Jul 14. doi: 10.1002/ijc.30888.
    PubMed     Abstract available

  153. GU F, Zhang H, Hyland PL, Berndt S, et al
    Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia.
    Int J Cancer. 2017 Jul 12. doi: 10.1002/ijc.30883.
    PubMed     Abstract available

  154. KNIPS J, Czech-Sioli M, Spohn M, Heiland M, et al
    Spontaneous lung metastasis formation of human Merkel cell carcinoma cell lines transplanted into scid mice.
    Int J Cancer. 2017;141:160-171.
    PubMed     Abstract available

    May 2017
  155. XIE K, Chen M, Zhu M, Wang C, et al
    A polymorphism in miR-1262 regulatory region confers the risk of lung cancer in Chinese population.
    Int J Cancer. 2017 May 16. doi: 10.1002/ijc.30788.
    PubMed     Abstract available

  156. NAJMEH S, Cools-Lartigue J, Rayes RF, Gowing S, et al
    Neutrophil extracellular traps sequester circulating tumor cells via beta1-integrin mediated interactions.
    Int J Cancer. 2017;140:2321-2330.
    PubMed     Abstract available

  157. MEYERS TJ, Chang SC, Chang PY, Morgenstern H, et al
    Case-control study of cumulative cigarette tar exposure and lung and upper aerodigestive tract cancers.
    Int J Cancer. 2017;140:2040-2050.
    PubMed     Abstract available

    April 2017
  158. LOBB RJ, van Amerongen R, Wiegmans A, Ham S, et al
    Exosomes derived from mesenchymal non-small cell lung cancer cells promote chemoresistance.
    Int J Cancer. 2017 Apr 26. doi: 10.1002/ijc.30752.
    PubMed     Abstract available

  159. BEN KHEDHER S, Neri M, Papadopoulos A, Christiani DC, et al
    Menstrual and reproductive factors and lung cancer risk: A pooled analysis from the International Lung Cancer consortium (ILCCO).
    Int J Cancer. 2017 Apr 25. doi: 10.1002/ijc.30750.
    PubMed     Abstract available

  160. WANG SS, Zimmermann M, Zhang H, Lin TY, et al
    A Diagnostic Microdosing Approach to Investigate Platinum Sensitivity in Non-Small Cell Lung Cancer.
    Int J Cancer. 2017 Apr 24. doi: 10.1002/ijc.30747.
    PubMed     Abstract available

  161. GROMOWSKI T, Gapska P, Scott RJ, Kaklewski K, et al
    Serum 25(OH)D concentration, common variants of the VDR gene and lung cancer occurrence.
    Int J Cancer. 2017 Apr 15. doi: 10.1002/ijc.30740.
    PubMed     Abstract available

  162. GOWING SD, Chow SC, Cools-Lartigue JJ, Chen CB, et al
    Gram-Positive Pneumonia Augments Non-Small Cell Lung Cancer Metastasis Via Host Toll-like Receptor 2 Activation.
    Int J Cancer. 2017 Apr 12. doi: 10.1002/ijc.30734.
    PubMed     Abstract available

  163. CAROZZI FM, Bisanzi S, Carrozzi L, Falaschi F, et al
    Multimodal lung cancer screening using the ITALUNG Biomarker Panel and Low Dose Computed Tomography. Results of the ITALUNG biomarker study.
    Int J Cancer. 2017 Apr 7. doi: 10.1002/ijc.30727.
    PubMed     Abstract available

  164. HELLAND A, Brustugun OT, Nakken S, Halvorsen AR, et al
    High number of kinome-mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival.
    Int J Cancer. 2017 Apr 7. doi: 10.1002/ijc.30726.
    PubMed     Abstract available

  165. LIN J, Gill A, Zahm SH, Carter CA, et al
    Metformin Use and Survival after Non-Small Cell Lung Cancer: A Cohort Study in the U.S. Military Health System.
    Int J Cancer. 2017 Apr 5. doi: 10.1002/ijc.30724.
    PubMed     Abstract available

  166. FRANK C, Sundquist J, Yu H, Hemminki A, et al
    Concordant and discordant familial cancer: Familial risks, proportions and population impact.
    Int J Cancer. 2017;140:1510-1516.
    PubMed     Abstract available

  167. RAASCHOU-NIELSEN O, Pedersen M, Stafoggia M, Weinmayr G, et al
    Outdoor air pollution and risk for kidney parenchyma cancer in 14 European cohorts.
    Int J Cancer. 2017;140:1528-1537.
    PubMed     Abstract available

  168. TANG Z, Li J, Shen Q, Feng J, et al
    Contribution of upregulated dipeptidyl peptidase 9 (DPP9) in promoting tumoregenicity, metastasis and the prediction of poor prognosis in non-small cell lung cancer (NSCLC).
    Int J Cancer. 2017;140:1620-1632.
    PubMed     Abstract available

    March 2017
  169. DONG J, Cheng Y, Zhu M, Wen Y, et al
    Fine Mapping of Chromosome 5p15.33 Identifies Novel Lung Cancer Susceptibility Loci in Han Chinese.
    Int J Cancer. 2017 Mar 23. doi: 10.1002/ijc.30702.
    PubMed     Abstract available

    Estimation of the tumor size at cure threshold among aggressive non-small cell lung cancers (NSCLCs): evidence from the surveillance, epidemiology, and end results (SEER) program and the national lung screening trial (NLST).
    Int J Cancer. 2017;140:1280-1292.
    PubMed     Abstract available

  171. SHI H, Zhang J, Han X, Li H, et al
    Recruited monocytic myeloid-derived suppressor cells promote the arrest of tumor cells in the premetastatic niche through an IL-1beta-mediated increase in E-selectin expression.
    Int J Cancer. 2017;140:1370-1383.
    PubMed     Abstract available

    January 2017
  172. ZHANG LL, Kan M, Zhang MM, Yu SS, et al
    Multiregion sequencing reveals the intratumor heterogeneity of driver mutations in TP53-driven non-small cell lung cancer.
    Int J Cancer. 2017;140:103-108.
    PubMed     Abstract available

  173. KAMMERER-JACQUET SF, Crouzet L, Brunot A, Dagher J, et al
    Independent association of PD-L1 expression with noninactivated VHL clear cell renal cell carcinoma-A finding with therapeutic potential.
    Int J Cancer. 2017;140:142-148.
    PubMed     Abstract available

  174. VAZQUEZ R, Licandro SA, Astorgues-Xerri L, Lettera E, et al
    Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts.
    Int J Cancer. 2017;140:197-207.
    PubMed     Abstract available

    December 2016
  175. MANDRIOTA SJ, Tenan M, Ferrari P, Sappino AP, et al
    Aluminium chloride promotes tumorigenesis and metastasis in normal murine mammary gland epithelial cells.
    Int J Cancer. 2016;139:2781-2790.
    PubMed     Abstract available

    November 2016
  176. LI L, Yang L, Wang L, Wang F, et al
    Impaired T cell function in malignant pleural effusion is caused by TGF-beta derived predominantly from macrophages.
    Int J Cancer. 2016;139:2261-9.
    PubMed     Abstract available

    October 2016
  177. TRABERT B, Eldridge RC, Pfeiffer RM, Shiels MS, et al
    Pre-diagnostic circulating inflammation markers and endometrial cancer risk in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial.
    Int J Cancer. 2016 Oct 22. doi: 10.1002/ijc.30478.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.